New biotech startup targets genes to treat skin diseases

A new biotech startup developing immuno-dermatology technologies for skin diseases has launched today with $100mn (€93mn) in seed funding. Based in Boston and Geneva, Alys Pharmaceuticals is co-founded by Medicixi, a European healthcare-focused investment firm, and six university scientists, including Nobel Prize winner Craig Mello. The startup is a merger of six individual companies in the field (also backed by Medicixi), which in combination boast 14 active R&D programmes. Alys is targeting chronic autoimmune skin conditions, including atopic dermatitis (eczema), alopecia areata (loss of hair), vitiligo (discoloration of the skin), and spontaneous urticaria (hives). For context, 1 in 10 individuals…

This story continues at The Next Web